M
Miqin Zhang
Researcher at University of Washington
Publications - 248
Citations - 31195
Miqin Zhang is an academic researcher from University of Washington. The author has contributed to research in topics: Cancer & Nanofiber. The author has an hindex of 77, co-authored 232 publications receiving 27498 citations. Previous affiliations of Miqin Zhang include University of California, Berkeley & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Magnetic Nanoparticles in MR Imaging and Drug Delivery
TL;DR: A background on applications of MNPs as MR imaging contrast agents and as carriers for drug delivery and an overview of the recent developments in this area of research are provided.
Journal ArticleDOI
Chitosan-based hydrogels for controlled, localized drug delivery
TL;DR: The newest developments in chitosan hydrogel preparation are investigated and the design parameters in the development of physically and chemically cross-linked hydrogels are defined.
Journal ArticleDOI
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging
TL;DR: The design parameters that affect MNP performance in vivo are summarized, including the physicochemical properties and nanoparticle surface modifications, such as MNP coating and targeting ligand functionalizations that can enhance MNP management of biological barriers.
Journal ArticleDOI
Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake.
TL;DR: PEG and folic acid modification of magnetite nanoparticles could be used to resist the protein adsorption and thus avoid the particle recognition by macrophage cells, and to facilitate the nanoparticle uptake to specific cancer cells for cancer therapy and diagnosis.
Journal ArticleDOI
Chitosan-alginate hybrid scaffolds for bone tissue engineering.
TL;DR: Coacervation of chitosan and alginate combined with liquid-solid separation provides a scaffold with high porosity, and mechanical and biological properties suitable for rapid advancement into clinical trials.